|
Jan 12
|
Insider Sell: EVP, Chief Commercial Officer Benjamin Hickey Sells Shares of Mirati Therapeutics Inc
|
|
Jan 11
|
Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC
|
|
Jan 10
|
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
|
|
Dec 27
|
FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras
|
|
Dec 20
|
Mirati Therapeutics Inc EVP & Chief Scientific Officer Jamie Christensen Sells 2,387 Shares
|
|
Dec 15
|
Insider Sell Alert: EVP Benjamin Hickey Sells Shares of Mirati Therapeutics Inc (MRTX)
|
|
Dec 12
|
Billionaire Joe Lewis Keeps Trading Stocks Behind US Insider-Trading Charges
|
|
Sep 27
|
Mirati To Present Updated Clinical Data at ESMO Congress 2023
|
|
Sep 10
|
Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung Cancer
|
|
Aug 11
|
Mirati Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
|
|
Aug 10
|
Penn downgraded, Roblox upgraded: Wall Street's top analyst calls
|
|
Aug 9
|
Mirati Rockets 33% On A Bevy Of News In Cancer, A $300 Million Deal And Its CEO Exit
|
|
Aug 9
|
Cancer Discovery Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers through Novel Approach to MTA-Cooperative PRMT5 Inhibition
|
|
Aug 9
|
Why Shares of Mirati Therapeutics Are Jumping Wednesday
|
|
Aug 9
|
Mirati (MRTX) Q2 Earnings Beat, Stock Up on Solid Krazati Sales
|
|
Aug 9
|
Q2 2023 Mirati Therapeutics Inc Earnings Call
|
|
Aug 9
|
Mirati Therapeutics Announces Pricing of Upsized Public Offering
|
|
Aug 8
|
Mirati Therapeutics Announces Proposed Public Offering
|
|
Aug 8
|
Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
|
|
Aug 8
|
Mirati Therapeutics Announces Departure of Chief Executive Officer David Meek
|